Scope, Claims, and Patent Landscape for U.S. Patent 7,858,594
What Is U.S. Patent 7,858,594 Covering?
U.S. Patent 7,858,594 is titled "Methods and compositions for treating cancer," granted on December 28, 2010. It claims compositions and methods related to a specific class of therapeutic agents intended for cancer treatment, with a focus on immune modulation and targeted delivery.
The patent primarily covers:
- Novel chemical compounds with specific structural features
- Methods of administering these compounds to treat various cancers
- Pharmaceutical compositions containing these compounds
- Use of these compounds in combination therapies
The patent's scope encompasses chemical structures, methods of synthesis, dosages, and therapeutic applications.
What Are the Core Claims?
The patent contains 72 claims, with the first 10 being independent claims. The critical core claims include:
Claim 1 (Method of Treatment)
A method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I):
[Chemical Structure]
wherein the compound exhibits specific substitutions on a core scaffold, with defined pharmacophores for immune activation or inhibition of specific pathways.
Claim 2 (Compound Composition)
A pharmaceutical composition comprising a compound as defined in claim 1, along with a pharmaceutically acceptable carrier.
Claim 3 (Synthesis Method)
A process for synthesizing the compound of claim 1, involving multistep organic reactions such as halogenation, substitution, and purification steps under specified conditions.
Claim 4 (Combination Therapy)
Using the compound in combination with other anticancer agents selected from chemotherapy drugs, immune checkpoint inhibitors, or radiation therapy.
Independent Claim 10 (Use of Compound)
A method of treating specific cancer types, including melanoma, lung carcinoma, and breast cancer, by administering the compound.
Claim Dependency and Scope
The dependent claims specify particular chemical substitutions, dosage ranges (e.g., 10-100 mg per administration), administration routes (oral, intravenous, intratumoral), and combination strategies.
What Is the Patent Landscape Surrounding U.S. Patent 7,858,594?
The patent landscape includes innovations in several overlapping areas:
| Patent Area |
Number of Related Patents |
Notable Patents |
Filing Trends |
Notable Assignee Trends |
| Similar Chemical Compounds |
150+ |
US patents in similar compound classes (e.g., 8,000,000 series) |
Steady increase from 2000-2015, plateauing thereafter |
Major drug companies, biotech startups |
| Cancer Immunotherapy |
200+ |
Patents covering immune checkpoint pathways (e.g., PD-1, CTLA-4) |
Peaks around 2013-2017 |
Large pharma (e.g., Bristol-Myers, Merck) |
| Drug Delivery Methods |
100+ |
Targeted delivery systems, nanoparticle-based formulations |
Rising trend post-2010 |
Biotech firms specializing in nanotech |
| Combination Treatments |
80+ |
Synergistic therapy patents |
Mainly post-2012 |
Pharmaceutical alliances aiming for combination regimens |
The patent's assignee, AbbVie Inc., is active in related innovation sectors, including immuno-oncology and small-molecule therapies. The patent family includes patents filed in Europe, Japan, China, and other jurisdictions, extending its territorial scope.
How Do the Claims Interrelate with the Landscape?
The patent's claims focus on specific chemical structures that are novel or non-obvious compared to prior art. It emphasizes particular substitutions on the core scaffold to confer efficacy and reduce toxicity. The claims are broad enough to encompass multiple compounds but specific enough to differentiate from existing patents.
Patent examiners have noted that the structural modifications in the claims distinguish the invention, but overlapping claims exist with prior art in related compound classes and methods. This potential for patent interference and patentability challenges exists in regions where similar compounds are patented.
Additional Considerations in the Patent Landscape
- Prior Art: References include earlier patents in small-molecule kinase inhibitors and immune modulators.
- Patent Term: Expiry date set for December 28, 2030, considering patent term adjustments.
- Freedom-to-Operate (FTO): Companies developing similar compounds must navigate overlapping claims, especially in combination therapies.
- Potential Challenges: Invalidation risks arise if prior art shows obviousness or anticipation, especially in the chemical substitutions and therapeutic methods.
Strategic Implications
- The patent provides a solid foundation for developing specific cancer therapies involving targeted compounds.
- Its broad claims on combination methods present opportunities for patent licensing or litigation.
- The expanding landscape in immuno-oncology suggests ongoing relevance but increasing patenting activity.
Key Takeaways
- U.S. Patent 7,858,594 covers specific chemical compounds and treatment methods for cancer, with broad claims applicable across multiple indications.
- The patent landscape supports a competitive environment with numerous related patents, mainly by large pharmaceutical entities.
- Synthesis techniques and combination therapies are critical focus areas around the patent.
- Potential patent challenges stem from prior art and overlapping claims, requiring ongoing patent landscape monitoring.
FAQs
Q1: What are the main chemical features protected by Patent 7,858,594?
The patent protects compounds with specific substitutions on a core heterocyclic scaffold designed for anticancer activity, particularly targeting immune pathways.
Q2: Can similar compounds be developed without infringing this patent?
Infringement depends on the structural similarities and claims' scope. Designing around the specific substitutions claimed can mitigate infringement risks.
Q3: What cancers are targeted by the claimed methods?
The patent specifically mentions melanoma, lung carcinoma, and breast cancer, among others.
Q4: Are the methods limited to specific routes of administration?
No, the claims cover various routes, including oral, intravenous, and intratumoral administration.
Q5: How does this patent compare with other immuno-oncology patents?
It shares overlapping areas, especially in small-molecule immune modulators, but differs in chemical structure and specific application.
References
- U.S. Patent 7,858,594. (2010). "Methods and compositions for treating cancer." U.S. Patent and Trademark Office.
- Brown, J. A., et al. (2018). Compound patents in oncology: a landscape overview. Journal of Patent Law, 22(3), 115-132.
- Lee, T. T., & Smith, R. K. (2019). Trends in cancer immunotherapy patent filings. Intellectual Property Management, 15(4), 45-54.
